Experimental studies have shown that PDPK1 is a potential therapeutic target for breast cancer 26, 27, pancreatic cancer 28, esophageal cancer 29, lymphoma 30, and melanoma 31, 32. This evidence concerns the gene PDPK1 and familial pancreatic carcinoma.